Published in J Proteomics Bioinform on June 18, 2011
The hallmarks of cancer. Cell (2000) 113.05
A power primer. Psychol Bull (1992) 63.66
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Cancer genes and the pathways they control. Nat Med (2004) 24.22
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell (2009) 7.09
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Outlier sums for differential gene expression analysis. Biostatistics (2006) 2.75
Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin Cancer Res (1997) 1.94
Cancer outlier differential gene expression detection. Biostatistics (2006) 1.87
MOST: detecting cancer differential gene expression. Biostatistics (2007) 1.21
Serum autoantibody profiling using a natural glycoprotein microarray for the prognosis of early melanoma. J Proteome Res (2010) 0.97
LSOSS: Detection of Cancer Outlier Differential Gene Expression. Biomark Insights (2010) 0.94
Cancer outlier detection based on likelihood ratio test. Bioinformatics (2008) 0.91
The distribution-based p-value for the outlier sum in differential gene expression analysis. Biometrika (2010) 0.81
The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med (2007) 13.39
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry (2011) 6.66
GAGE: generally applicable gene set enrichment for pathway analysis. BMC Bioinformatics (2009) 3.86
Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells (2007) 3.60
Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood (2007) 2.16
Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res (2007) 2.14
Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene (2005) 1.99
Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood (2008) 1.93
Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res (2008) 1.74
Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum. J Proteome Res (2006) 1.65
Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res (2007) 1.62
A pathobiological role of the insulin receptor in chronic lymphocytic leukemia. Clin Cancer Res (2011) 1.54
N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis. J Proteome Res (2007) 1.51
Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin Cancer Res (2011) 1.50
Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood (2011) 1.44
Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. J Proteome Res (2007) 1.32
Pancreatic cancer serum detection using a lectin/glyco-antibody array method. J Proteome Res (2009) 1.30
Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J Proteome Res (2008) 1.29
Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood (2010) 1.27
Identification of cell surface glycoprotein markers for glioblastoma-derived stem-like cells using a lectin microarray and LC-MS/MS approach. J Proteome Res (2010) 1.23
Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. Blood (2010) 1.23
Membrane glycoproteins associated with breast tumor cell progression identified by a lectin affinity approach. J Proteome Res (2008) 1.21
Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. Clin Cancer Res (2010) 1.18
Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS. J Proteome Res (2012) 1.17
Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood (2014) 1.16
CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. Mol Cell Proteomics (2011) 1.16
Microarray analysis of gene expression during the cell cycle. Cell Chromosome (2003) 1.16
Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: a strategy for identification of candidate cancer biomarkers. Proteomics (2004) 1.15
Renal gene and protein expression signatures for prediction of kidney disease progression. Am J Pathol (2009) 1.15
Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia. Blood (2012) 1.15
Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia. Clin Cancer Res (2013) 1.15
Protein pI shifts due to posttranslational modifications in the separation and characterization of proteins. Anal Chem (2005) 1.14
Mass spectrometric assay for analysis of haptoglobin fucosylation in pancreatic cancer. J Proteome Res (2011) 1.14
A cheminformatic toolkit for mining biomedical knowledge. Pharm Res (2007) 1.13
Identification of glycoprotein markers for pancreatic cancer CD24+CD44+ stem-like cells using nano-LC-MS/MS and tissue microarray. J Proteome Res (2012) 1.13
Radiation produces differential changes in cytokine profiles in radiation lung fibrosis sensitive and resistant mice. J Hematol Oncol (2009) 1.11
Humoral response profiling reveals pathways to prostate cancer progression. Mol Cell Proteomics (2007) 1.09
NF1 inactivation in adult acute myelogenous leukemia. Clin Cancer Res (2010) 1.08
Serum metabolomic analysis of pancreatic cancer--letter. Cancer Epidemiol Biomarkers Prev (2013) 1.07
Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations. J Proteome Res (2010) 1.05
Combining physical and biologic parameters to predict radiation-induced lung toxicity in patients with non-small-cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys (2012) 1.05
Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies. J Proteome Res (2014) 1.05
Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis. J Proteome Res (2014) 1.04
Target proteomic profiling of frozen pancreatic CD24+ adenocarcinoma tissues by immuno-laser capture microdissection and nano-LC-MS/MS. J Proteome Res (2013) 1.03
A cell-based molecular transport simulator for pharmacokinetic prediction and cheminformatic exploration. Mol Pharm (2006) 1.03
Proteomic analysis of rat pheochromocytoma PC12 cells. Proteomics (2006) 1.03
A two-dimensional liquid-phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification. Proteomics (2004) 1.02
Early detection and biomarkers in pancreatic cancer. J Natl Compr Canc Netw (2007) 1.02
Screening of glycosylation patterns in serum using natural glycoprotein microarrays and multi-lectin fluorescence detection. Anal Chem (2006) 1.01
Glycoproteomic analysis of glioblastoma stem cell differentiation. J Proteome Res (2010) 1.00
Identification of metastasis-associated proteins in a human tumor metastasis model using the mass-mapping technique. Proteomics (2004) 1.00
Analysis of glycan variation on glycoproteins from serum by the reverse lectin-based ELISA assay. J Proteome Res (2014) 1.00
Urine glycoprotein profile reveals novel markers for chronic kidney disease. Int J Proteomics (2011) 0.99
The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia. Clin Cancer Res (2011) 0.99
A comparison of drug-treated and untreated HCT-116 human colon adenocarcinoma cells using a 2-D liquid separation mapping method based upon chromatofocusing PI fractionation. Anal Chem (2003) 0.99
Data mining the NCI60 to predict generalized cytotoxicity. J Chem Inf Model (2008) 0.99
Proteomic analysis of cytokeratin isoforms uncovers association with survival in lung adenocarcinoma. Neoplasia (2002) 0.98
A 2-D liquid separations/mass mapping method for interlysate comparison of ovarian cancers. Anal Chem (2002) 0.98
Comparative proteomic study of two closely related ovarian endometrioid adenocarcinoma cell lines using cIEF fractionation and pathway analysis. Electrophoresis (2009) 0.97
Serum autoantibody profiling using a natural glycoprotein microarray for the prognosis of early melanoma. J Proteome Res (2010) 0.97
Quantitative proteomic profiling studies of pancreatic cancer stem cells. J Proteome Res (2010) 0.95
Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia. Genes Chromosomes Cancer (2012) 0.95
Characterization of apolipoprotein and apolipoprotein precursors in pancreatic cancer serum samples via two-dimensional liquid chromatography and mass spectrometry. J Chromatogr A (2007) 0.94
A protein molecular weight map of ES2 clear cell ovarian carcinoma cells using a two-dimensional liquid separations/mass mapping technique. Electrophoresis (2002) 0.94
Classifications of ovarian cancer tissues by proteomic patterns. Proteomics (2006) 0.94
Classification of cancer cell lines using an automated two-dimensional liquid mapping method with hierarchical clustering techniques. Mol Cell Proteomics (2005) 0.93
Proteomics in melanoma biomarker discovery: great potential, many obstacles. Int J Proteomics (2011) 0.92
Proteomic analysis of a membrane skeleton fraction from human liver. J Proteome Res (2007) 0.92
Altered expression of sialylated glycoproteins in ovarian cancer sera using lectin-based ELISA assay and quantitative glycoproteomics analysis. J Proteome Res (2013) 0.91
Proteomic analysis of estrogen response of premalignant human breast cells using a 2-D liquid separation/mass mapping technique. Proteomics (2006) 0.90
Protein microarrays using liquid phase fractionation of cell lysates. Proteomics (2003) 0.90
A multiplexed bead assay for profiling glycosylation patterns on serum protein biomarkers of pancreatic cancer. Electrophoresis (2011) 0.89
Comparative proteomics analysis of Barrett metaplasia and esophageal adenocarcinoma using two-dimensional liquid mass mapping. Mol Cell Proteomics (2006) 0.89
The identification of phosphoglycerate kinase-1 and histone H4 autoantibodies in pancreatic cancer patient serum using a natural protein microarray. Electrophoresis (2009) 0.89
Label-free relative quantification of alpha-2-macroglobulin site-specific core-fucosylation in pancreatic cancer by LC-MS/MS. Electrophoresis (2013) 0.89
Proteomic profiling identifies breast tumor metastasis-associated factors in an isogenic model. Proteomics (2007) 0.87
The second golden age of glycomics: from functional glycomics to clinical applications. J Proteome Res (2009) 0.87
Glycoprotein analysis using protein microarrays and mass spectrometry. Mass Spectrom Rev (2010) 0.86
Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma. J Proteome Res (2014) 0.86
Comparative proteomic analysis of radiation-induced changes in mouse lung: fibrosis-sensitive and -resistant strains. Radiat Res (2008) 0.86
Enrichment of glycoproteins using nanoscale chelating concanavalin A monolithic capillary chromatography. Anal Chem (2009) 0.86
High sequence coverage of proteins isolated from liquid separations of breast cancer cells using capillary electrophoresis-time-of-flight MS and MALDI-TOF MS mapping. Anal Chem (2003) 0.86
Differential phosphoprotein mapping in cancer cells using protein microarrays produced from 2-D liquid fractionation. Anal Chem (2006) 0.86
Comparative proteomic analysis of B. cenocepacia using two-dimensional liquid separations coupled with mass spectrometry. Anal Chim Acta (2007) 0.86
System dynamics of subcellular transport. Mol Pharm (2005) 0.85
Differential expression of ribosomal proteins in a human metastasis model identified by coupling 2-D liquid chromatography and mass spectrometry. Cancer Genomics Proteomics (2007) 0.85
Two-dimensional liquid chromatography protein expression mapping for differential proteomic analysis of normal and O157:H7 Escherichia coli. Biotechniques (2003) 0.85
Tenascin-C: a novel candidate marker for cancer stem cells in glioblastoma identified by tissue microarrays. J Proteome Res (2014) 0.84
Isobaric protein-level labeling strategy for serum glycoprotein quantification analysis by liquid chromatography-tandem mass spectrometry. Anal Chem (2013) 0.84